Checkpoint Therapeutics Inc (NASDAQ: CKPT) on Tuesday, soared 0.25% from the previous trading day, before settling in for the closing price of $4.05. Within the past 52 weeks, CKPT’s price has moved between $1.38 and $4.50.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -46.76%. The company achieved an average annual earnings per share of 72.34%. With a float of $35.93 million, this company’s outstanding shares have now reached $45.10 million.
Let’s determine the extent of company efficiency that accounts for 23 employees. In terms of profitability, gross margin is -45168.08%, operating margin of -79817.02%, and the pretax margin is -98868.09%.
Checkpoint Therapeutics Inc (CKPT) Breakdown of a Key Holders of the stock
Observing investor behavior towards Biotechnology industry stocks is more important than anything else. The insider ownership of Checkpoint Therapeutics Inc is 26.43%, while institutional ownership is 41.40%. The most recent insider transaction that took place on Feb 10 ’25, was worth 32,543. In this transaction CEO, President and Director of this company sold 10,331 shares at a rate of $3.15, taking the stock ownership to the 3,775,019 shares. Before that another transaction happened on Feb 07 ’25, when Company’s CEO, President and Director sold 9,233 for $3.41, making the entire transaction worth $31,485. This insider now owns 3,785,350 shares in total.
Checkpoint Therapeutics Inc (CKPT) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.1 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 72.34% per share during the next fiscal year.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Trading Performance Indicators
Checkpoint Therapeutics Inc (CKPT) is currently performing well based on its current performance indicators. A quick ratio of 0.29 was reported for the most recent quarter. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3965.20.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.44, a number that is poised to hit -0.16 in the next quarter and is forecasted to reach -0.26 in one year’s time.
Technical Analysis of Checkpoint Therapeutics Inc (CKPT)
Looking closely at Checkpoint Therapeutics Inc (NASDAQ: CKPT), its last 5-days average volume was 1.44 million, which is a drop from its year-to-date volume of 2.54 million. As of the previous 9 days, the stock’s Stochastic %D was 90.00%. Additionally, its Average True Range was 0.16.
During the past 100 days, Checkpoint Therapeutics Inc’s (CKPT) raw stochastic average was set at 79.39%, which indicates a significant decrease from 98.83% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 195.16% in the past 14 days, which was higher than the 106.09% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $3.27, while its 200-day Moving Average is $2.90. However, in the short run, Checkpoint Therapeutics Inc’s stock first resistance to watch stands at $4.06. Second resistance stands at $4.07. The third major resistance level sits at $4.07. If the price goes on to break the first support level at $4.05, it is likely to go to the next support level at $4.05. Now, if the price goes above the second support level, the third support stands at $4.04.
Checkpoint Therapeutics Inc (NASDAQ: CKPT) Key Stats
Market capitalization of the company is 198.26 million based on 48,833K outstanding shares. Right now, sales total 100 K and income totals -51,850 K. The company made 40 K in profit during its latest quarter, and -6,670 K in sales during its previous quarter.
